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Ligands for identifying protein aggregates are of great interest as such deposits are the pathological
hallmark of a wide range of severe diseases including Alzheimer's and Parkinson's disease. Here we
report the synthesis of an azide functionalized ﬂuorescent pentameric oligothiophene that can be
utilized as a ligand for multimodal detection of disease-associated protein aggregates. The azide
functionalization allows for attachment of the ligand to a surface by conventional click chemistry
without disturbing selective interaction with protein aggregates and the oligothiophene–aggregate
interaction can be detected by ﬂuorescence or surface plasmon resonance. In addition, a methodology
where the oligothiophene ligand is employed as a capturing molecule selective for aggregated proteins in
combination with an antibody detecting a distinct peptide/protein is also presented. We foresee that this
methodology will offer the possibility to create a variety of multiplex sensing systems for sensitive and
selective detection of protein aggregates, the pathological hallmarks of several neurodegenerative
diseases.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Ligands for visualization, identiﬁcation and characterization of
protein aggregates are of great interest as such deposits are
associated with many devastating diseases (Sipe et al., 2012).
These protein deposits, termed “amyloid” or inclusion bodies,
result from the misfolding and/or partial unfolding of proteins,
which results in the formation of protein aggregates. From a
biophysical perspective, amyloid deposits consist of ﬁbrils with a
diameter around 10 nm and structural studies of amyloid have
shown that the protein or peptide molecules are arranged so that
the polypeptide chain forms β-strands that run perpendicular to
the axis of the ﬁbril (Petkova et al., 2002; Ritter et al., 2005; Makin
et al., 2005; Nelson et al., 2005). Since most amyloid ﬁbrils have
extensive cross β-pleated sheet conformation and sufﬁcient struc-
tural regularity, small hydrophobic amyloid ligands targeting this
core structure have been developed. The most common ligands for
classiﬁcation of protein aggregates in tissue or identiﬁcation ofB.V. This is an open access article u
.
cience and Technology, 7491in vitro formed amyloid ﬁbrils are derivatives of Congo red or
Thioﬂavins (Bennhold, 1922; Divry, 1927; Naiki et al., 1989; LeVine,
1993). In addition, other chemical scaffolds, such as stilbene
derivatives (Kung et al., 2001; Ono et al., 2005), vinylbenzoxazole
derivatives (Shimadzu et al., 2004; Kudo et al., 2007) and mole-
cular frameworks, including derivatives of ﬂuorene, thiophene,
biphenyl thiophene, and biphenyltriene (Furumoto et al., 2007;
Nesterov et al., 2005; Raymond et al., 2008), have also been
utilized for the development of amyloid-speciﬁc ligands.
Lately, chemically-deﬁned molecular scaffolds consisting of
repetitive thiophene moieties, denoted luminescent conjugated
oligothiophenes (LCOs), have proven to be a remarkable class of
ﬂuorescent molecules for investigating protein deposits associated
with protein aggregation diseases, such as Alzheimer’s disease
(AD) and Parkinson's disease (PD), as well as the infectious prion
diseases (Åslund et al., 2009; Lord et al., 2011; Klingstedt et al.,
2011, 2013; Nyström et al., 2013). In comparison with conventional
ligands, LCOs identify a broader sub-set of disease-associated
protein deposits and heterogenic populations of protein aggre-
gates could also be distinguished due to distinct spectroscopic
signatures from these dyes. Hence, LCO can be utilized as ﬂuor-
escent ligands for sensitive detection and spectral assignment of a
plethora of disease-associated protein deposits.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Chemical structures and optical properties of the oligothiophene ligands. A) Chemical structures of p-FTAA (top) and p-FTAA-azide (bottom). B) Absorption spectra of
3 μM p-FTAA (blue) or 3 μM p-FTAA-azide (red) in PBS. C) Emission spectra of 300 nM p-FTAA (blue) or 300 nM p-FTAA-azide (red) in PBS (lines) or mixed with 10 μM
recombinant Aβ amyloid ﬁbrils in PBS (dotted lines). D) Excitation spectra of 300 nM p-FTAA (blue) or 300 nM p-FTAA-azide (red) in PBS (solid lines) or mixed with 10 μM
recombinant Aβ amyloid ﬁbrils in PBS (dotted lines). Emission at 515 nm. E) Binding curve showing the ratio, Ratio455/405 nm, of the intensity of the emitted light at the
respective excitation maximum, 455 nm (bound dye) and 405 nm (unbound dye) against different dye concentration. Different concentrations of p-FTAA (blue) or p-FTAA-
azide (red) in PBS (lines) or mixed with 10 μM recombinant Aβ amyloid ﬁbrils in PBS (dotted lines).
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identify protein aggregates and it would be of great interest to
modify this class of compounds for multimodal detection of
protein aggregates. Properly functionalized LCOs that can be
covalently attached to a surface will also allow the development
of versatile LCO-based sensing systems for a variety of protein
aggregates. Recently, we introduced a pentameric oligothiophene
with a porphyrin moiety linked to the thiophene backbone via a
tetra ethylene glycol spacer and this hybrid molecule allowed for
improved ﬂuorescent assessment of heterogeneous amyloid
morphologies compared to the corresponding oligothiophene
dye (Arja et al., 2013). Herein, we introduce an azide-functiona-
lized pentameric oligothiophene ligand that can be utilized for
copper-free click chemistry (Agard et al., 2004; Ning et al., 2008)
and evaluate the potential of utilizing this molecule as a multi-
modal ligand towards protein aggregates. The azide-functionalized
oligothiophene ligand, p-FTAA-azide (Fig. 1A), exhibited an ex-
cellent speciﬁcity towards recombinant Aβ (M1-42) amyloid ﬁbrils
and Aβ-deposits in tissue sections from transgenic mice with AD
pathology. In addition, the azide functionality could be utilized for
attaching the molecule to a solid support without losing the
amyloid speciﬁcity and p-FTAA-azide could be implemented as a
tool for detecting protein aggregates by surface plasmon reso-
nance (SPR).2. Materials and methods
2.1. Synthesis of p-FTAA and p-FTAA-azide
The synthesis of p-FTAA has been reported previously (Åslund
et al., 2009) and the synthesis of p-FTAA-azide is described below
and in Scheme 1.2.2. General methods
NMR-spectra were recorded on a Varian 300 MHz instrument,
using CDCl3 as solvent. Chemical shifts were assigned with the
solvent residual peak as a reference (Gottlieb et al., 1997). TLC was
carried out on Merck pre-coated 60 F254 plates using UV-light
(λ¼254 nm and 366 nm) and charring with ethanol/sulfuric acid/
p-anisaldehyde/acetic acid 90:3:2:1 for visualization. Flash column
chromatography (FC) was performed using silica gel 60 (0.040–
0.063 mm, Merck). Organic phases were dried over anhydrous
magnesium sulfate. Solvents were evaporated with a rotary
evaporator under reduced pressure (1–2 kPa) at a water bath
temperature of 40 °C. HPLC-MS was performed on a Gilson system
(Column: Waters X-Bridge C-18 or C-8 5 m, 25015 mm2 and
Waters X-Bridge C-18 or C-8 2.5 m, 1504.6 mm2 for semipre-
parative and analytical runs respectively; Pump: Gilson gradient
pump 322; UV/vis-detector: Gilson 155; MS detector: Thermo
Finnigan Surveyor MSQ; Gilson Fraction Collector FC204) using
acetonitrile with 0.05% ammonium acetate and deionized water
with 0.05% ammonium acetate as mobile phase. MALDI-TOF MS
was recorded on a Voyager-DESTR Biochemistry workstation.
2.3. Synthesis of 1
Compound 1 was synthesized as described previously (Chen
and Baker, 1999). PEG-Diol (8.9 mL, 51.3 mmol) and p-toluenesul-
fonyl chloride (29.45 g, 154.5 mmol) were dissolved in THF (60 mL)
and stirred for 5 min at 0 °C, then a solution of KOH (18.94 g,
337 mmol) dissolved in H2O (21 mL) was added drop wise over
20 min. The ice bath was removed and the reaction was stirred
overnight. After 16 h ice cold water (50 mL) was added, and the
aqueous layer extracted with Et2O (3* 50 mL). The collected
organic phases were washed with Brine (2* 50 mL) dried over
MgSO4, ﬁltered and evaporated to give 1 as clear oil. (23.81 g, 92%).
Scheme 1. The synthesis of p-FTAA-azide. Reagents and conditions: i) p-TsCl, THF, KOH/H20, 0 °C, r.t. ii) NaN3, DMF 110 °C, r.t. iii) PPh3, Et2O, H3P04 (aq.), iv) DIPEA, HATU,
DMF, r.t. v) 1) TFA, DCM, r.t. 2) NaOH, Dioxane/H20, r.t.
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J¼6.0 Hz, 4H), 4.15 (t, J¼6.0 Hz, 4H), 7.34 (d, J¼9.0 Hz, 4H),
7.79 (t, J¼9.0 Hz, 4H).
2.4. Synthesis of 2
Compound 2 was synthesized as described previously
(Schwabacher et al., 1998). 1 (13.061 g, 25.987 mmol) was dis-
solved in DMF (150 mL) and NaN3 (5.078 g, 78.111 mmol) was
added portion wise. The reaction mixture was heated to 110 °C for
3 h and then cooled to room temperature. After evaporation the
mixture was re-dissolved in ethyl acetate (EtOAc), and the un-
dissolved sodium salt was ﬁltered off and the organic layer
evaporated. This procedure was repeated six times to give the
crude product as yellow oil. The crude product was puriﬁed by
Flash Column Chromatography (toluene/EtOAc 4:1) to yield 2 as
colorless oil (6.139 g, 97%, (Rf¼0.28, T/EtOAc 4:1)).
1H-NMR (CDCl3, 300MHz): δ 3.39 (t, J¼5.3 Hz, 4H), 3.68 (m, 12H).
13C-NMR (CDCl3, 75.5 MHz): δ 50.8, 70.2, 70.8.2.5. Synthesis of 3
2 (1.010 g, 4.135 mmol) was stirred in aqueous H3PO4 (0.65 M,
20 mL) then PPh3 (0.935 g, 3.566 mmol) dissolved in Et2O (15 mL)
was added drop wise over 45 min. The mixture was stirred
vigorously under N2-atmosphere for 24 h. The aqueous layer was
separated and washed three times with Et2O and KOH was added
to get a basic solution. Et2O was evaporated and the solution
cooled overnight in a refrigerator. The precipitated Ph3PO was
ﬁltered off, the aqueous phase extracted with DCM, dried over
Na2SO4, ﬁltered and evaporated to give crude product as dark
brown oil. The crude product was puriﬁed by Flash Column
Chromatography (EtOAc/MeOH 4:1þ1% TEA) and the chloride salt
was obtained by adding 1.5 eq. 1M HCl to yield 3 as colorless oil
(0.378 g, 42%).
1H-NMR (CDCl3, 300 MHz): δ 3.18 (t, J¼5.3 Hz, 2H), 3.40 (t,
J¼5.3 Hz, 2H), 3.65 (m, 10H), 3.75 (t, J¼5.0 Hz, 2H), 6.36 (s, 3H).
13C-NMR (CDCl3, 75.5MHz): δ 40.1, 51.0, 67.6, 70.0, 70.4, 70.6,
70.6, 70.7.
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Compound 4 was synthesized from a previously reported
compound, q-FTAM (Klingstedt et al., 2011). The compound was
tert-Butyl protected, then brominated followed by Suzuki coupling
of a carboxythiophene moiety, the detailed synthesis will be
published elsewhere (Manuscript in preparation).
2.7. Synthesis of 5
4 (0.050 g, 0.071 mmol) and 3 (0.050 g, 0.180 mmol) were
dissolved in DMF (1.5 mL) and then DIPEA (0.100 mL, 0.574 mmol)
was added. After 10 min HATU (0.059 g, 0.155 mmol) was added
and the reaction mixture was stirred at room temperature for 2 h,
the reaction was monitored by HPLC/MS. Puriﬁcation by gradient
HPLC/MS gave pure 5 as orange-yellow oil (0.0569 g, 89%).
1H-NMR (CDCl3, 300 MHz): δ 1.59 (s, 9H), 3.36 (t, J¼5.0 Hz, 2H),
3.66 (m, 14H), 3.75 (s, 6H), 3.78 (s, 4H), 6.55 (t, J¼4.7 Hz, 1H),
7.11 (d, J¼4.1 Hz, 2H), 7.19 (s, 2H), 7.21 (d, J¼5.3 Hz, 2H), 7.42
(d, J¼4.1 Hz, 1H), 7.61 (d, J¼4.1 Hz, 1H).
13C-NMR (CDCl3, 75.5 MHz): δ 28.5, 35.0, 40.1, 51.0, 52.4, 70.0,
70.2, 70.6, 70.9, 70.9, 71.0, 82.1, 124.2, 127.9, 128.2, 128.2, 128.9,
131.7, 133.0, 133.2, 133.6, 135.6, 135.7, 135.7, 135.7, 141.1, 142.6,
161.3, 161.7, 170.9.
2.8. Synthesis of 6 (p-FTAA-azide)
5 (0.054 g, 0.060 mmol) was dissolved in DCM (2.0 mL), then
TFA (1.0 mL) was added and the mixture stirred at room tempera-
ture for 2 h. After evaporation and co-evaporation with toluene,
re-dissolved in dioxane (1.0 mL) and H2O (0.5 mL), then NaOH 1M
(0.36 mL, 0.358 mmol) was added and mixture stirred at room
temperature for 2 h. Then evaporated and puriﬁed by gradient
HPLC/MS. The sodium salt was obtained by adding 4.5 eq. 1 M
NaOH yielding 6 (0.060 g, 93%) as red powder.
1H-NMR (D2O, 300 MHz): δ 3.37 (t, J¼5.7 Hz 2H), 3.42 (t, J¼4.9
Hz, 2H), 3.58 (m, 16H), 6.85 (d, J¼3.9 Hz, 1H), 6.89 (s, 2H), 6.94
(d, J¼3.8 Hz 1H), 7.08 (s, 1H), 7.10 (s, 1H), 7.32 (d, J¼3.9 Hz, 1H),
7.42 (d, J ¼3.8 Hz, 1H).
13C-NMR (D2O, 75.5 MHz): δ 38.4, 39.3, 50.1, 68.6, 69.2, 69.5,
110.0, 124.1, 126.1, 126.2, 129.0, 129.5, 131.7, 131.8, 132.4, 133.1,
133.9, 134.2, 134.2, 134.8, 134.9, 135.1, 139.4, 140.7, 141.7, 163.3,
168.4, 169.2, 178.6, 178.8.
FT-IR vmax (KBr-pellet): 630, 772, 804, 1114, 1302, 1379, 1456,
1519, 1575, 2100, 2866, 3325 cm-1
MALDI-TOF: for C34H32N4O10S5, [MþH]þ calcd: 817.08; found:
816.17, [MþNa]þ calcd: 839.06 found: 839.17 [MþK]þ calcd:
855.04 found: 855.12
2.9. Optical characterization of p-FTAA and p-FTAA-azide
p-FTAA and p-FTAA-azide were dissolved in deionized water
to a ﬁnal concentration of 1.5 mM and further diluted to a
concentration of 3 μM (absorption measurements) or 300 nm
(excitation- and emission measurements) in PBS (10 mM phos-
phate buffer supplemented with 140 mM NaCl and 2.7 mM KCl, pH
7.4). After 10 min of incubation, emission spectra were collected
between 480–700 nm using a Tecan Saphire 2 plate reader (Tecan
Group Ltd., Männedorf, Switzerland) with excitation at 420 nm.
Similarly, excitation spectra were recorded between 340–520 nm
having the emission ﬁxed at the respective emission maxima. Inaddition, absorption spectra were measured between 380 and
650 nm.
2.10. Characterization of p-FTAA and p-FTAA-azide bound to Aβ
(M1-42) amyloid ﬁbrils
Recombinant Aβ (M1-42) was prepared as reported previously
(Walsh et al., 2009). The peptide was dissolved in PBS to a ﬁnal
concentration of 10 μM and Aβ (M1-42) amyloid ﬁbrils were
prepared according to a previously described protocol
(Klingstedt et al., 2011). p-FTAA (15 μM in deionized water) or
p-FTAA-azide (15 μM in deionized water) were added to pure
buffer (10 mM sodium-phosphate pH 7.5) or to 10 μM Aβ (M1-42)
amyloid ﬁbrils to a ﬁnal concentration of 300 nm. Excitation- and
emission spectra were collected as described above.
2.11. Tissue staining with p-FTAA and p-FTAA-azide
Cryosections (20 μm) of tissue from APP23 transgenic mice
with AD pathology were ﬁxed with ethanol for 10 min, re-
hydrated with deionized water, incubated with PBS for 10 min
and then stained for 30 min at room temperature with p-FTAA or
p-FTAA-azide. Both of the probes were diluted 1:500 in PBS from a
1.5 mM stock solution (deionized water). After rinsing with PBS
three times, the sections were mounted with Dako ﬂuorescence
mounting medium (Dako Cytomation, Glostrup, Denmark). The
medium was allowed to solidify for 3 h before the rims were
sealed with nail polish. Immunostaining of Aβ aggregates was
performed as described previously (Klingstedt et al., 2011). Spec-
tral images of stained tissue sections were acquired on an inverted
Zeiss (Axio Observer.Z1) LSM 780 microscope equipped with a 32
channel QUASAR GaAsP spectral array detector. For all imaging,
excitation was done by an argon laser at 458 nm. Emission spectra
were collected between 416 to 687 nm.
2.12. Tissue staining with p-FTAA or p-FTAA-azide in combination
with Click-ITs Alexa Fluors 594 DIBO Alkyne
Cryosections (20 μm) of tissue from APP23 transgenic mice
with AD pathology were stained with p-FTAA or p-FTAA-azide as
described above. After rinsing with PBS, the tissue was incubated
with 40 μM Click-ITs Alexa Fluors 594 DIBO Alkyne (Life Tech-
nologies Corporation) in PBS for 1 h. After rinsing with PBS ﬁve
times, the sections were mounted with Dako ﬂuorescence mount-
ing medium (Dako Cytomation, Glostrup, Denmark). The medium
was allowed to solidify for 3 h before the rims were sealed with
nail polish. Spectral images were recorded as described above.
2.13. Attachment of p-FTAA-azide to magnetic beads
Dynabeadss M-270 Carboxylic Acid (Life Technologies Cor-
poration) were washed with HEPES-buffered saline containing
EDTA and P20 (HBS-EP; 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA, 0.005% P20) for 10 min with good mixing. Next the beads
were incubated with 50 μl N-(3-Dimethylaminopropyl)-N′-ethyl-
carbodiimide (EDC 50 mg/ml) and 50 μl N-Hydroxysuccinimide
(NHS 50 mg/ml) in HEPES buffer for 1 h. After washing the beads
three times with HEPES buffer, the beads were incubated with
150 μM Dibenzocyclooctyne-amine (DBCO-amine, Sigma Aldrich)
in HEPES buffer. After incubation for 1 h, the beads were washed
three times with HEPES buffer and incubated with 75 μM p-FTAA
or 75 μM p-FTAA azide in HEPES buffer for 20 h. Finally, the beads
were washed ﬁve times with HEPES buffer. The beads were
visualized with the same microscope set up as described above.
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Surface plasmon resonance data were recorded using a Biacore
3000 instrument (GE Healthcare, Uppsala, Sweden) at 25 °C.
HEPES-buffered saline containing EDTA and P20 (HBS-EP; 10 mM
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% P20) and PBS, pH
7.4, were used as running buffers. A CM5 chip was functionalized
with the DBCO-amine using conventional amine coupling chem-
istry (EDC/NHS) as described above. The DBCO-amine (150 μM,
50 μL) was immobilized to the activated dextran matrix at a ﬂow
rate of 5 μL/min and p-FTAA-azide (150 μM, 50 μL) was also
injected at a ﬂow rate of 5 μL/min. Aβ (M1-42) native, (10 μM,
50 μL), Aβ (M1-42) ﬁbrils (5 or 10 μM, 50 μL), and antibody
(1 μg/mL, 50 μL), were injected at a ﬂow rate of 20 μL/min.
Sensorgrams were evaluated using BIAevaluation software version
4.1 (GE Healthcare).3. Results and discussion
3.1. Synthesis and optical characterization of p-FTAA-azide bound to
recombinant Aβ 1-42 ﬁbrils
To achieve an oligothiophene amyloid ligand that can be
utilized for click chemistry, an azide moiety was attached to the
pentameric LCO, p-FTAA (Fig. 1A), via a tetraethylene glycol spacer
(Scheme 1). By this approach, the resulting molecule, p-FTAA-
azide (Fig. 1A), has an amyloid-speciﬁc moiety, the oligothiophene,Fig. 2. Fluorescence images and emission spectra of Aβ-deposits in brain tissue section
p-FTAA, B) 3 μM p-FTAA-azide, D) 3 μM p-FTAA and 40 μM Alexa 594 DIBO or E) 3 μM p-F
with p-FTAA (blue) and p-FTAA-azide (red). F) Emission spectra from Aβ-deposits stain
(red). The images and the spectra were collected using an excitation at 458 nm. Scale band the azide group, which allows for the attachment of the ligand
to other entities such as a solid support. p-FTAA-azide dissolved in
phosphate buffered saline pH 7.4 (PBS) showed a slightly red
shifted absorption spectrum compared to p-FTAA with an absorp-
tion maximum at 422 nm, indicating that the attachment of the
azide functionalized tetraethylene glycol spacer leads to a slightly
more planar molecule (Fig. 1B). Upon excitation at 420 nm, the
emission maximum for p-FTAA-azide (emission max: 564 nm) was
also red shifted compared to p-FTAA (emission max: 545 nm) and
the ﬂuorescence observed was decreased p-FTAA-azide (Fig. 1C),
suggesting that the planarization of the molecule leads to stacking
of adjacent oligothiophene molecules.
To investigate if p-FTAA-azide bound to recombinant Aβ (M1-
42) amyloid ﬁbrils in a similar fashion as p-FTAA, emission and
excitation spectra of the ligands bound to recombinant Aβ (M1-
42) amyloid ﬁbrils generated in vitro were recorded. The emission
spectra from 300 nM p-FTAA-azide mixed with 10 μM Aβ (M1-42)
amyloid ﬁbrils showed similar emission characteristics as p-FTAA
(Fig. 1C). In agreement with previous studies (Åslund et al., 2009;
Klingstedt et al., 2011), p-FTAA bound to Aβ 1-42 amyloid ﬁbrils
displayed a spectrumwith two well-deﬁned emission maxima and
the intensity of the emission was also increased. p-FTAA-azide
bound to Aβ 1-42 amyloid ﬁbrils showed an increased emission
intensity with a slightly red-shifted spectrum with less resolved
double peaks compared to p-FTAA. As reported previously (Åslund
et al., 2009; Klingstedt et al., 2011), the excitation spectra reveals
more evident difference between free and bound ligand compared
to the emission spectra. Having the emission ﬁxed at thes from a transgenic mouse with AD pathology. Tissue sections stained by A) 3 μM
TAA-azide and 40 μM Alexa 594 DIBO. C) Emission spectra from Aβ-deposits stained
ed with p-FTAA and Alexa 594 DIBO (blue) and p-FTAA-azide and Alexa 594 DIBO
ars represent 50 μm.
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peaks around 430, 455 and 485 nm for both p-FTAA and p-FTAA-
azide bound to Aβ 1-42 amyloid ﬁbrils, whereas the free ligands
(unbound) in PBS displayed identical blue shifted spectra with a
broad excitation maximum (Fig. 1D). Overall, these experiments
clearly showed that p-FTAA-azide bound to Aβ 1-42 amyloid ﬁbrils
in an analogous fashion as p-FTAA.
By plotting the ratio, Ratio455/405nm, of the intensity of the
emitted light at the respective excitation maximum, 455 nm
(bound dye) and 405 nm (unbound dye) against the dye concen-
tration, binding curves can be generated (Fig. 1E). From these plots
apparent dissociation constants for the “highly emissive” binding
site can be estimated and compared for the two molecules. For
p-FTAA-azide, a hyperbolic curve was achieved and the ratio
reached a maximum at 150 nM dye. At lower concentration, the
ratio decreased and at the lowest concentration detectable with
the instrument, 1 nM dye, a ratio similar to only free dye in
solution was obtained (Fig. 1E). In contrast, p-FTAA displayed a
similar ratio over the entire concentration range with only a slight
decrease of the ratio at 1 nM dye (Fig. 1E). Hence, p-FTAA
displayed a stronger afﬁnity towards recombinant Aβ 1-42 amy-
loid ﬁbrils than p-FTAA-azide, suggesting that extending the
pentameric thiophene backbone with an azide functionalized
tetraethylene glycol moiety slightly weakens the afﬁnity of the
dye towards amyloid ﬁbrils. However, the apparent Kd for p-FTAA-
azide bound to recombinant Aβ 1-42 amyloid ﬁbrils could be
estimated to approximately 10 nM, implicating that binding of
p-FTAA-azide towards the ﬁbrils are fairly strong.
3.2. p-FTAA-azide bound to Aβ deposits in brain tissue sections
As we previously have utilized LCOs for spectral assignment of
protein aggregates in tissue sections (Åslund et al., 2009; Lord
et al., 2011; Klingstedt et al., 2011, 2013; Nyström et al., 2013), weFig. 3. Transmission and ﬂuorescence images of oligothiophene labeled magnetic bea
Transmission (A), ﬂuorescence (B) and merged (C) images of magnetic bead labeled with
labeled with p-FTAA-azide. Scale bars represent 50 mm.next applied p-FTAA-azide for histological staining of brain tissue
sections from transgenic mice with Alzheimer's disease (AD)
pathology. Similar to p-FTAA, p-FTAA-azide showed selective and
speciﬁc staining of immuno-positive Aβ deposits (Fig. 2A and B,
Fig. S1; Supplemental material). Aggregated Aβ species could
easily be identiﬁed due to intense emission from both of the
ligands, and the two ligands also displayed comparable emission
spectra (Fig. 2C). Hence, similar to the observation on recombinant
Aβ ﬁbrils, the attachment of the azide functionalized tetraethylene
glycol spacer to the oligothiophene backbone did not prevent the
speciﬁc binding of the ligand to Aβ deposits in tissue sections.
To verify if the azide functionality was still accessible when
p-FTAA-azide was bound to the Aβ deposits, we incubated the
oligothiophene stained tissue samples with Click-ITs Alexa Fluors
594 DIBO Alkyne (Life Technologies Corporation), a ﬂuorescent dye
with a cyclooctyne moiety that is reactive towards azides via a
copper-free click chemistry reaction (Agard et al., 2004; Ning et al.,
2008). When using excitation at 458 nm, Aβ deposits pre-stained
by p-FTAA showed a uniform green color (Fig. 2D), whereas
individual Aβ deposits pre-stained by p-FTAA-azide displayed a
red color (Fig. 2E). Spectral analysis of the p-FTAA-azide pre-
stained deposits revealed a decrease in the intensity of the
oligothiophene emission and a novel dominant peak at 617 nm
was observed (Fig. 2F). In contrast, the p-FTAA pre-stained
deposits displayed a characteristic p-FTAA spectrum (Fig. 2F).
Hence, the emission peak, 617 nm, from the Alexa Fluors 594
dye could only be observed from the p-FTAA-azide pre-stained Aβ
deposits, verifying that the click chemistry reaction between the
cyclooctyne moiety and the azide functionality was successful.
Overall, these experiments veriﬁed that p-FTAA-azide displayed
speciﬁc labeling of Aβ-deposits in tissue samples and that the
azide functionality could be assessed for additional chemical
modiﬁcations when the ligand was bound to protein aggregates.ds. Images of magnetic beads treated with p-FTAA (A–C) or p-FTAA-azide (D–F).
p-FTAA. Transmission (D), ﬂuorescence (E) and merged (F) images of magnetic bead
L.B.G. Johansson et al. / Biosensors and Bioelectronics 63 (2015) 204–2112103.3. Attachment of p-FTAA-azide to magnetic beads
To validate the accessibility of the azide moiety for attaching
the ligand to a solid support, we next tested a click chemistry
based protocol for attaching p-FTAA-azide to carboxy functiona-
lized magnetic beads. The magnetic beads were ﬁrst treated with
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) and N-
Hydroxysuccinimide (NHS) followed by incubation with Dibenzo-
cyclooctyne-amine (DBCO-amine) to introduce a cyclooctyne moi-
ety on the surface. When incubated with p-FTAA in PBS, the DBCO-
amine functionalized magnetic beads could only by viewed in
transmission mode and no signal was obtained in ﬂuorescence
mode (Fig. 3A–C), indicating that non-speciﬁc binding of p-FTAA to
the beads was very low. In contrast, functionalized beads incu-
bated with p-FTAA-azide displayed an intense green ﬂuorescence
(Fig. 3D–F). Thus, the click chemistry reaction between the
cyclooctyne moiety and p-FTAA-azide was effective and the click
chemistry based protocol could be utilized for attaching the azide
functionalized ligand to a solid support, the magnetic beads.Fig. 4. SPR sensorgrams and a schematic picture of a multiarray based on LCO-capture
antibody detection. The activated dextran surface is functionalized with DBCO-amine and
click-chemistry. Upon injection of Aβ (M1-42) ﬁbrils the ﬁbrils are captured by the LCO a
injected. B) Sensorgram of p-FTAA-azide (150 μM) injected over a DBCO-amine functi
functionalized surface. D) Sensorgrams of 10 μM Aβ (M1-42) ﬁbrils (red line) or 10 μM fr
6E10 (1 μg/mL) (2) injected over a p-FTAA-azide functionalized surface. E) Sensorgram o
line) and a 1:1 Langmuir ﬁt for Kd-evaluation (blue line).3.4. Utilization of p-FTAA-azide for surface plasmon resonance
measurements
The intrinsic ﬂuorescence of LCOs has been utilized to identify
protein aggregates and although this property has provided novel
information regarding protein aggregates (Åslund et al., 2009;
Wegenast-Braun et al., 2012; Nyström et al., 2013; Klingstedt et al.,
2013; Heilbronner et al., 2013), experimental set-ups allowing multi-
modal or extrinsic detection of the LCO-aggregate interactions would
be advantageous. In addition, a versatile LCO-based multiplex sensing
system for a variety of protein aggregates would be of great interest,
since such assays could provide the basis for early detection of distinct
protein aggregation diseases. Preferably, a capturing assay for protein
aggregates would be comprised of both a capture ligand speciﬁc for
aggregated proteins, and an antibody speciﬁc for a distinct protein.
Thus, the capture ligand will be selective for aggregated species of the
protein, whereas the antibody will verify the identity of the protein
similar to recently presented assays utilizing peptoid-based capture
reagents in combination with antibodies (Lau et al., 2007; Yam et al.,
2011). To explore the prospect of creating an LCO-based capturing/ antibody detection. A) Schematic drawing of a multiarray based on LCO-capture/
p-FTAA-azide is subsequently covalently bound to the surface through copper-free
nd to verify the nature of the aggregate entities an antibody (6E10) speciﬁc for Aβ is
onalized surface, C) Sensorgram of p-FTAA (150 μM) injected over a DBCO-amine
eshly dissolved recombinant native Aβ (M1-42) peptide (blue line) (1) and antibody
f 5 mM Aβ (M1-42) ﬁbrils injected over a p-FTAA-azide functionalized surface (red
L.B.G. Johansson et al. / Biosensors and Bioelectronics 63 (2015) 204–211 211assay, p-FTAA-azide was evaluated in a BiaCore system, allowing
attachment of the ligand to a surface and real time detection of the
LCO-aggregate interaction with surface plasmon resonance (SPR)
(Fig. 4A). In a similar fashion as described above, a gold chip with a
carboxymethylated dextran matrix (Sensor Chip CM5, GE Healthcare)
was ﬁrst treated with EDC and NHS followed by incubation with
DBCO-amine to introduce a cyclooctyne moiety on the surface. After
injection of p-FTAA-azide, a SPR response (100 RU) was obtained,
whereas no signal was obtained after injecting p-FTAA (Fig. 4B and C).
Hence, the p-FTAA-azide could be attached to the sensor surface
through a rather straight forward click chemistry based protocol.
Next, we injected freshly dissolved native recombinant Aβ (M1-42)
or in vitro generated recombinant Aβ (M1-42) amyloid ﬁbrils. For the
p-FTAA-azide functionalized channel, a SPR response (300 RU) was
observed after injection of the amyloid ﬁbrils, (Fig. 4D). In contrast, the
response was considerably lower for the channel injected with native
peptide, verifying that speciﬁcity towards protein aggregates was
obtained after attaching p-FTAA-azide to the surface (Fig. 4D). After
injection of an antibody speciﬁc for Aβ (6E10), the SPR response was
increased further, (300RU), verifying that the aggregated species
captured on the LCO functionalized surface contained Aβ-peptides
(Fig. 4D). Thus, the p-FTAA-azide functionalized surface displayed a
pronounced selectivity towards protein aggregates and the identity of
these aggregates could be veriﬁed by a subsequent injection of an
antibody towards a distinct protein. By analyzing For the reference
channel, a DBCO-amine functionalized surface, no responses were
obtained when injecting in vitro generated recombinant Aβ (M1-42)
amyloid ﬁbrils, as well as an antibody speciﬁc for Aβ (Fig. S2,
Supplemental material). An apparent Kd of 8.3 nM for 5 μM Aβ (M1-
42) binding to p-FTAA-azide functionalized surface was determined by
ﬁtting the curve to a 1:1 Langmuir model (Fig. 4E).This value was in
the same order of magnitude as the apparent Kd value estimated from
the ﬂuorescence measurements (Fig. 1E). Overall, we conclude that the
methodology, utilizing a combination of a LCO-based capturing
molecule and an antibody speciﬁc for a distinct peptide/protein, might
provide a multiplex sensing system for a variety of protein aggregates
and a schematic representation of such a system is outlined in Fig. 4A.4. Conclusions
In conclusion, we have shown that an azide-functionalized
oligothiophene-based amyloid ligand, p-FTAA-azide, can be uti-
lized for multimodal sensing of protein aggregates. The azide
functionality offers the possibility of attaching oligothiophene-
based amyloid ligands to a solid support without disturbing the
selectivity of the interaction with protein aggregates. We foresee
that p-FTAA-azide and other similar derivatives will be used as
additional molecular tools for studying the formation of protein
aggregates, as well as for creating a variety of sensing systems for
sensitive and selective detection of the pathological hallmarks of
protein aggregation diseases.Acknowledgments
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